Ferric Citrate Market

Report Overview

The Global Ferric Citrate Market is expected to be worth around USD 1829.8 Million by 2034, up from USD 547.2 Million in 2024, and grow at a CAGR of 12.8% from 2025 to 2034. North America holds 38.0% of the Ferric Citrate market, valued at USD 208.0 Million.

Ferric Citrate is a chemical compound that consists of iron and citric acid and is often used as a source of iron supplementation. It is primarily utilized in medical applications to treat iron deficiency anemia and is also used as a phosphate binder in patients with chronic kidney disease (CKD), helping to reduce phosphate levels in the blood. Ferric citrate works by providing bioavailable iron, which is essential for the production of red blood cells and the proper functioning of various enzymes in the body.

The global ferric citrate market has been expanding, largely driven by the increasing prevalence of chronic kidney disease (CKD) and iron deficiency anemia. As the global population ages and the number of CKD patients grows, the demand for phosphate binders such as ferric citrate has surged, especially in developed markets such as North America and Europe, where high-quality healthcare and advanced treatments are widely accessible. Additionally, the rising awareness of iron deficiency, particularly in women and children, has contributed to a steady demand for iron supplements, further boosting the market for ferric citrate.

In the pharmaceutical sector, ferric citrate’s dual role as an iron supplement and a phosphate binder makes it valuable for managing both iron deficiency and high phosphate levels in CKD patients. Furthermore, as healthcare systems in developing countries improve and access to treatments increases, the ferric citrate market is expected to grow significantly in these regions. The market faces challenges from alternative iron supplements and phosphate binders, but continuous research and innovation in the formulation and delivery of ferric citrate products are expected to support its growth.

Key Takeaways

• The global ferric citrate market was valued at US$ 547.2 million in 2024.
• The global ferric citrate market is projected to grow at a CAGR of 12.8% and is estimated to reach US$ 1,829.8 million by 2034.
• Among grades, pharmaceutical grade accounted for the largest market share of 86.5%.
• Among applications, pharmaceuticals accounted for the majority of the market share at 86.5%.
• North America is estimated as the largest market for ferric citrate with a share of 38.0% of the market share.
• Asia-Pacific is anticipated to register the highest CAGR of 14.1%.
• Europe with a revenue share of 34.6% in 2024 and expected to register a CAGR of 12.9%.

Grade Analysis

Simple Ferric Citrates Dominated the Market, Owing to Their Widespread Application Across Various Industries

The ferric citrate market is segmented based on pharmaceutical grade, food grade, and others. In 2024, the grade simple ferric citrates segment held a significant revenue share of 86.5% due to its critical role in managing chronic kidney disease (CKD) and iron deficiency anemia. Ferric citrate, in its pharmaceutical-grade form, is primarily used as a phosphate binder for CKD patients undergoing dialysis, helping to control elevated phosphate levels in the blood. This is a key factor driving its demand, as the global prevalence of CKD continues to rise with the aging population and increasing lifestyle-related health issues. Pharmaceutical-grade ferric citrate is specifically designed to meet strict quality standards for bioavailability, purity, and safety, making it highly effective for managing both iron deficiency and phosphate levels in patients with complex health needs.

The growing incidence of iron deficiency anemia, particularly in vulnerable populations such as pregnant women, elderly individuals, and those with chronic illnesses, further boosts the demand for pharmaceutical-grade ferric citrate, as it is considered one of the more effective treatments for replenishing iron levels.

Additionally, the regulatory approvals and clinical recommendations for pharmaceutical-grade ferric citrate in key markets such as North America and Europe also contribute to its strong market share. Furthermore, the dual functionality of pharmaceutical-grade ferric citrate, acting as both an iron supplement and a phosphate binder, positions it as an essential component in the treatment regimens for CKD patients, solidifying its dominant role in the market. As healthcare awareness and access continue to improve globally, the demand for pharmaceutical-grade ferric citrate is expected to remain strong.

Global Ferric Citrate Market, By Grade, 2020-2024 (USD Mn)

Key Regions and Countries

• North America
  • The US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia & CIS
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • ASEAN
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of MEA

Market Share & Key Players Analysis

To Maintain a Competitive Edge, Major Companies In The Ferric Citrate Market Focus On Product Innovation and Research & Development (R&D)

The ferric citrate market is highly competitive, with major companies employing a variety of strategic approaches to maintain their market position and drive growth. Ferric citrate is widely used in the pharmaceutical sector for treating iron-deficiency anemia and chronic kidney disease (CKD), as well as in food additives, agriculture, and industrial applications. Leading manufacturers adopt product differentiation, research and development (R&D), strategic partnerships, market expansion, and cost optimization to sustain their market leadership.

The following are some of the major players in the industry

• American Elements
• FUJIFILM Wako Pure Chemical Corporation
• DC Fine Chemicals S. L.
• Global Calcium Pvt. Ltd.
• Lifeasible
• Jost Chemical Co.
• West Bengal Chemical Industries Limited
• ALPHA CHEMIKA
• Shanghai Chemex
• SimSon Pharma Limited
• Central Drug House Pvt. Ltd.
• Other Key Players

Key Development

28 June 2018: Akebia Therapeutics acquired Keryx Biopharmaceuticals, the original developer of Auryxia® (ferric citrate), allowing them to expand their presence in the pharmaceutical market for kidney disease treatments.